 Edwin Liu
Concepts (307)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 58 | 2023 | 264 | 10.480 |
Why?
| | Autoantibodies | 44 | 2023 | 1346 | 3.170 |
Why?
| | Transglutaminases | 26 | 2023 | 142 | 2.980 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 174 | 2.020 |
Why?
| | Autoimmune Diseases | 8 | 2019 | 382 | 1.800 |
Why?
| | Diabetes Mellitus, Type 1 | 45 | 2019 | 3252 | 1.480 |
Why?
| | Diet, Gluten-Free | 8 | 2023 | 30 | 1.430 |
Why?
| | Autoimmunity | 21 | 2023 | 813 | 1.340 |
Why?
| | Insulin | 23 | 2009 | 2078 | 1.330 |
Why?
| | Genetic Predisposition to Disease | 20 | 2023 | 2085 | 1.270 |
Why?
| | GTP-Binding Proteins | 10 | 2021 | 139 | 1.210 |
Why?
| | Peptide Fragments | 14 | 2008 | 666 | 1.180 |
Why?
| | Glutens | 10 | 2023 | 56 | 1.020 |
Why?
| | HLA-DR3 Antigen | 3 | 2015 | 79 | 0.950 |
Why?
| | Islets of Langerhans | 16 | 2017 | 726 | 0.930 |
Why?
| | HLA-DR Antigens | 5 | 2017 | 219 | 0.790 |
Why?
| | Insulin Antibodies | 10 | 2013 | 102 | 0.740 |
Why?
| | Genetic Testing | 6 | 2015 | 379 | 0.690 |
Why?
| | Down Syndrome | 2 | 2023 | 335 | 0.650 |
Why?
| | Patient Compliance | 2 | 2023 | 525 | 0.610 |
Why?
| | Child | 36 | 2023 | 18412 | 0.560 |
Why?
| | Child, Preschool | 25 | 2023 | 9114 | 0.530 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2006 | 160 | 0.520 |
Why?
| | Mice, Inbred NOD | 20 | 2013 | 555 | 0.520 |
Why?
| | Caregivers | 1 | 2022 | 717 | 0.490 |
Why?
| | Mass Screening | 7 | 2023 | 1004 | 0.490 |
Why?
| | Depression | 2 | 2022 | 1134 | 0.470 |
Why?
| | Poly I-C | 4 | 2008 | 51 | 0.430 |
Why?
| | Humans | 74 | 2023 | 114662 | 0.420 |
Why?
| | Gliadin | 3 | 2018 | 12 | 0.400 |
Why?
| | Radioimmunoassay | 3 | 2016 | 162 | 0.380 |
Why?
| | Jejunum | 1 | 2011 | 24 | 0.370 |
Why?
| | Female | 47 | 2021 | 59493 | 0.360 |
Why?
| | Follow-Up Studies | 11 | 2020 | 4411 | 0.360 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 206 | 0.360 |
Why?
| | Infant | 20 | 2023 | 7961 | 0.350 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 87 | 0.350 |
Why?
| | Sensitivity and Specificity | 9 | 2017 | 1692 | 0.340 |
Why?
| | Prospective Studies | 17 | 2023 | 6219 | 0.330 |
Why?
| | Male | 39 | 2021 | 55583 | 0.320 |
Why?
| | Intestinal Mucosa | 3 | 2023 | 532 | 0.320 |
Why?
| | Risk Factors | 16 | 2020 | 8632 | 0.320 |
Why?
| | Liver Failure, Acute | 2 | 2008 | 58 | 0.320 |
Why?
| | Luminescent Measurements | 2 | 2020 | 74 | 0.310 |
Why?
| | Dietary Proteins | 2 | 2019 | 122 | 0.300 |
Why?
| | Adolescent | 17 | 2023 | 17841 | 0.300 |
Why?
| | Laboratories | 1 | 2009 | 95 | 0.300 |
Why?
| | Mice | 30 | 2013 | 14863 | 0.290 |
Why?
| | Immunoglobulin A | 7 | 2022 | 166 | 0.290 |
Why?
| | Interferon-alpha | 2 | 2005 | 186 | 0.280 |
Why?
| | Wheat Hypersensitivity | 1 | 2007 | 4 | 0.280 |
Why?
| | T-Lymphocytes | 7 | 2008 | 1737 | 0.280 |
Why?
| | Poly A-U | 1 | 2006 | 3 | 0.280 |
Why?
| | Immune Tolerance | 4 | 2013 | 323 | 0.270 |
Why?
| | Europe | 6 | 2017 | 334 | 0.270 |
Why?
| | Biopsy | 9 | 2023 | 1036 | 0.260 |
Why?
| | Serologic Tests | 4 | 2021 | 49 | 0.260 |
Why?
| | Polymorphism, Single Nucleotide | 6 | 2016 | 1879 | 0.250 |
Why?
| | HLA Antigens | 5 | 2019 | 225 | 0.240 |
Why?
| | Anaphylaxis | 2 | 2004 | 143 | 0.240 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 797 | 0.230 |
Why?
| | CD4 Antigens | 2 | 2003 | 123 | 0.230 |
Why?
| | Antibodies | 3 | 2014 | 371 | 0.230 |
Why?
| | Time Factors | 8 | 2017 | 6114 | 0.220 |
Why?
| | Animals | 32 | 2015 | 31698 | 0.220 |
Why?
| | Peptides | 3 | 2018 | 848 | 0.220 |
Why?
| | Diet | 4 | 2019 | 1080 | 0.220 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 45 | 0.220 |
Why?
| | Genotype | 7 | 2019 | 1760 | 0.220 |
Why?
| | Autoantigens | 6 | 2009 | 396 | 0.220 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2006 | 615 | 0.200 |
Why?
| | Predictive Value of Tests | 7 | 2015 | 1796 | 0.200 |
Why?
| | Biomarkers | 6 | 2023 | 3408 | 0.190 |
Why?
| | Proportional Hazards Models | 7 | 2019 | 1075 | 0.190 |
Why?
| | Mice, Transgenic | 7 | 2013 | 1947 | 0.180 |
Why?
| | Infant, Newborn | 8 | 2019 | 5045 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2008 | 959 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2313 | 0.170 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 482 | 0.170 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 70 | 0.170 |
Why?
| | Vaccines | 1 | 2004 | 375 | 0.170 |
Why?
| | Prevalence | 3 | 2023 | 2251 | 0.160 |
Why?
| | Diabetes Mellitus | 2 | 2007 | 900 | 0.160 |
Why?
| | Mice, Inbred BALB C | 7 | 2009 | 1143 | 0.160 |
Why?
| | Enterovirus | 1 | 2019 | 72 | 0.160 |
Why?
| | Probiotics | 1 | 2019 | 46 | 0.160 |
Why?
| | Duodenum | 3 | 2023 | 62 | 0.160 |
Why?
| | Risk Assessment | 8 | 2020 | 2968 | 0.160 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1262 | 0.150 |
Why?
| | Risk | 3 | 2019 | 812 | 0.150 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 284 | 0.150 |
Why?
| | Anxiety | 2 | 2022 | 840 | 0.150 |
Why?
| | Adoptive Transfer | 4 | 2008 | 195 | 0.150 |
Why?
| | Nutritionists | 1 | 2018 | 13 | 0.150 |
Why?
| | Feces | 1 | 2019 | 373 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 4408 | 0.140 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2016 | 13 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 46 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2006 | 3532 | 0.130 |
Why?
| | Cesarean Section | 1 | 2018 | 169 | 0.130 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 64 | 0.130 |
Why?
| | United States | 8 | 2023 | 12181 | 0.130 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 170 | 0.130 |
Why?
| | Gastroenteritis | 1 | 2016 | 65 | 0.130 |
Why?
| | HLA-DP beta-Chains | 1 | 2015 | 76 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2019 | 3003 | 0.120 |
Why?
| | Quality of Life | 2 | 2023 | 2353 | 0.120 |
Why?
| | Weight Gain | 1 | 2017 | 453 | 0.120 |
Why?
| | HLA-DR4 Antigen | 1 | 2014 | 76 | 0.120 |
Why?
| | Mice, Knockout | 8 | 2009 | 2568 | 0.110 |
Why?
| | ROC Curve | 3 | 2013 | 442 | 0.110 |
Why?
| | Parents | 1 | 2022 | 1186 | 0.110 |
Why?
| | Homozygote | 1 | 2014 | 187 | 0.110 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2013 | 367 | 0.110 |
Why?
| | Immunization | 3 | 2007 | 397 | 0.110 |
Why?
| | Child Development | 1 | 2017 | 385 | 0.110 |
Why?
| | International Cooperation | 2 | 2016 | 171 | 0.110 |
Why?
| | Clonal Anergy | 1 | 2013 | 53 | 0.100 |
Why?
| | Mice, SCID | 4 | 2008 | 314 | 0.100 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 150 | 0.100 |
Why?
| | Amino Acid Sequence | 3 | 2008 | 1982 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2023 | 12546 | 0.100 |
Why?
| | B-Lymphocyte Subsets | 1 | 2013 | 68 | 0.100 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 53 | 0.100 |
Why?
| | Breast Feeding | 1 | 2015 | 368 | 0.100 |
Why?
| | Sweden | 3 | 2017 | 65 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 811 | 0.100 |
Why?
| | Bone Density | 1 | 2015 | 432 | 0.100 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1481 | 0.100 |
Why?
| | Young Adult | 4 | 2023 | 10466 | 0.090 |
Why?
| | Heterozygote | 2 | 2016 | 251 | 0.090 |
Why?
| | Adenoviridae | 2 | 2019 | 184 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2006 | 687 | 0.090 |
Why?
| | Proinsulin | 3 | 2008 | 48 | 0.090 |
Why?
| | Plant Proteins | 1 | 2011 | 81 | 0.090 |
Why?
| | Mice, Inbred C57BL | 7 | 2013 | 4692 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4622 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2015 | 574 | 0.090 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1183 | 0.080 |
Why?
| | Decision Support Techniques | 1 | 2013 | 355 | 0.080 |
Why?
| | Prothrombin Time | 2 | 2008 | 34 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2538 | 0.080 |
Why?
| | Prediabetic State | 3 | 2009 | 219 | 0.080 |
Why?
| | Ammonia | 2 | 2008 | 56 | 0.080 |
Why?
| | Radioligand Assay | 1 | 2009 | 43 | 0.080 |
Why?
| | Bilirubin | 2 | 2008 | 88 | 0.080 |
Why?
| | Intracellular Fluid | 1 | 2008 | 27 | 0.080 |
Why?
| | Vaccines, DNA | 1 | 2008 | 29 | 0.080 |
Why?
| | Adult | 8 | 2023 | 30544 | 0.080 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 134 | 0.080 |
Why?
| | Immunoglobulin G | 2 | 2021 | 770 | 0.080 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2008 | 11 | 0.080 |
Why?
| | Spleen | 3 | 2007 | 487 | 0.080 |
Why?
| | Cohort Studies | 5 | 2017 | 4895 | 0.080 |
Why?
| | Hyperglycemia | 2 | 2008 | 291 | 0.080 |
Why?
| | Biopsy, Needle | 2 | 2011 | 182 | 0.070 |
Why?
| | Blood Glucose | 3 | 2006 | 1826 | 0.070 |
Why?
| | B7-1 Antigen | 2 | 2004 | 53 | 0.070 |
Why?
| | Cholera Toxin | 1 | 2007 | 27 | 0.070 |
Why?
| | Disease Progression | 5 | 2016 | 2380 | 0.070 |
Why?
| | Colorado | 1 | 2017 | 4099 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 98 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 316 | 0.070 |
Why?
| | Self-Help Groups | 1 | 2007 | 29 | 0.070 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 170 | 0.070 |
Why?
| | Genes, RAG-1 | 1 | 2006 | 11 | 0.070 |
Why?
| | Interferon-gamma | 2 | 2008 | 719 | 0.070 |
Why?
| | Crosses, Genetic | 1 | 2006 | 139 | 0.070 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 271 | 0.070 |
Why?
| | Logistic Models | 3 | 2017 | 1841 | 0.070 |
Why?
| | Antibody Formation | 1 | 2007 | 266 | 0.070 |
Why?
| | Intestine, Small | 1 | 2007 | 122 | 0.060 |
Why?
| | Pediatrics | 2 | 2016 | 979 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1842 | 0.060 |
Why?
| | Education, Continuing | 1 | 2006 | 39 | 0.060 |
Why?
| | Age Factors | 3 | 2017 | 2894 | 0.060 |
Why?
| | Survival Rate | 2 | 2007 | 1644 | 0.060 |
Why?
| | Isoelectric Point | 1 | 2004 | 22 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 13 | 0.060 |
Why?
| | B-Lymphocytes | 1 | 2009 | 766 | 0.060 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 84 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2785 | 0.060 |
Why?
| | Neonatal Screening | 1 | 2005 | 152 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 217 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2004 | 511 | 0.050 |
Why?
| | Epitopes | 1 | 2005 | 435 | 0.050 |
Why?
| | Genetic Markers | 2 | 2015 | 320 | 0.050 |
Why?
| | Immunotherapy | 1 | 2007 | 474 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2007 | 2763 | 0.050 |
Why?
| | Protein Precursors | 1 | 2003 | 119 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1342 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2008 | 2319 | 0.050 |
Why?
| | Anemia, Pernicious | 1 | 2002 | 9 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2004 | 778 | 0.050 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2002 | 18 | 0.050 |
Why?
| | Thyroid Diseases | 1 | 2002 | 30 | 0.050 |
Why?
| | Addison Disease | 1 | 2002 | 40 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 352 | 0.050 |
Why?
| | Oligopeptides | 1 | 2003 | 236 | 0.050 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2002 | 61 | 0.050 |
Why?
| | Prognosis | 2 | 2008 | 3329 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 8 | 0.050 |
Why?
| | Immunoglobulin D | 1 | 2021 | 27 | 0.050 |
Why?
| | Algorithms | 1 | 2008 | 1468 | 0.040 |
Why?
| | Survival Analysis | 1 | 2003 | 1211 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 75 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1421 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 246 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2387 | 0.040 |
Why?
| | Diet Records | 1 | 2019 | 76 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 314 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1394 | 0.040 |
Why?
| | Rats | 2 | 2004 | 4958 | 0.040 |
Why?
| | Infant Formula | 1 | 2019 | 74 | 0.040 |
Why?
| | Metagenomics | 1 | 2019 | 131 | 0.040 |
Why?
| | Population Surveillance | 1 | 2020 | 392 | 0.040 |
Why?
| | Behavior Therapy | 1 | 2020 | 226 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2017 | 116 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1214 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2002 | 376 | 0.040 |
Why?
| | Rotavirus | 1 | 2016 | 22 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 560 | 0.030 |
Why?
| | Phenotype | 3 | 2015 | 2796 | 0.030 |
Why?
| | Drug Utilization | 1 | 2017 | 167 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 48 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 743 | 0.030 |
Why?
| | China | 1 | 2016 | 161 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 213 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1528 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2019 | 460 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 718 | 0.030 |
Why?
| | Aging | 1 | 2005 | 1618 | 0.030 |
Why?
| | Vaccination | 1 | 2003 | 1204 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 520 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 90 | 0.030 |
Why?
| | Aggression | 1 | 2017 | 183 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 510 | 0.030 |
Why?
| | Protective Factors | 1 | 2015 | 87 | 0.030 |
Why?
| | Family Health | 1 | 2016 | 193 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 77 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 477 | 0.030 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 233 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 1958 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1078 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1448 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1629 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 319 | 0.030 |
Why?
| | Intestines | 1 | 2015 | 326 | 0.030 |
Why?
| | Sex Factors | 1 | 2017 | 1715 | 0.030 |
Why?
| | Administration, Oral | 2 | 2004 | 728 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 201 | 0.030 |
Why?
| | Base Sequence | 2 | 2008 | 2114 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 668 | 0.030 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2013 | 107 | 0.030 |
Why?
| | Glutamate Decarboxylase | 1 | 2012 | 160 | 0.020 |
Why?
| | Mothers | 1 | 2017 | 651 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 5518 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 383 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 562 | 0.020 |
Why?
| | Registries | 1 | 2017 | 1768 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 48 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 342 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 337 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 9 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 15 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2009 | 27 | 0.020 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2009 | 11 | 0.020 |
Why?
| | Europium | 1 | 2009 | 2 | 0.020 |
Why?
| | Biotinylation | 1 | 2009 | 26 | 0.020 |
Why?
| | Streptavidin | 1 | 2009 | 14 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1037 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2008 | 75 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2008 | 18 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 247 | 0.020 |
Why?
| | Plasmids | 1 | 2008 | 343 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 218 | 0.020 |
Why?
| | Cross-Priming | 1 | 2007 | 18 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2007 | 75 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2007 | 36 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 168 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 309 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 239 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 3885 | 0.020 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 22 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 561 | 0.010 |
Why?
| | Environmental Health | 1 | 2004 | 30 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 151 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2636 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 92 | 0.010 |
Why?
| | Age of Onset | 1 | 2004 | 446 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 53 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2094 | 0.010 |
Why?
| | Species Specificity | 1 | 2004 | 542 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 442 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 69 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1578 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 92 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 217 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2015 | 9088 | 0.010 |
Why?
| | Alleles | 1 | 2002 | 789 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 720 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 26733 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 2508 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 3345 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|